Direxion Daily Semicondct Bull 3X ETF

VS TR -1x Short VIX Futures ETF

Bank Of Montreal MAX S&P 500 4X Leveraged ETNs due October 30

Direxion Daily Small Cap Bull 3X ETF

Direxion Daily Technology Bull 3X ETF

ProShares UltraPro S&P500

Direxion Daily S&P500 Bull 3X ETF

Bank Of Montreal

Direxion Daily Financial Bull 3X ETF

ProShares UltraPro Dow30

VS TR 2x Long VIX Futures ETF

ProShares Ultra VIX Short-Term Futures

Direxion Daily Semicondct Bear 3X ETF

iPath S&P 500 VIX ST Futures ETN

Direxion Daily Small Cap Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Daily S&P 500 Bear 3X ETF

ProShares UltraPro Short S&P500

Direxion Financial Bear 3X Shar

AMC Entertainment Holdings Inc. Class A Common Stock

NuScale Power Corporation Class A Common Stock

Oklo Inc.

BlackBerry Limited Common Stock

Hillenbrand Inc Common Stock

JELD-WEN Holding Inc. Common Stock

RE/MAX Holdings Inc. Class A Common Stock

Olin Corporation Common Stock

Carnival Corporation Common Stock

Block Inc. Class A Common Stock

Virgin Galactic Holdings Inc. Common Stock

MINISO Group Holding Limited American Depositary Shares each representing four Ordinary Shares

Gold Fields Limited American Depositary Shares

NIO Inc. American depositary shares each  representing one Class A ordinary share

XPeng Inc. American depositary shares each representing two Class A ordinary shares

Grupo Aeroportuario Del Pacifico S.A. B. de C.V. Grupo Aeroportuario Del Pacifico S.A. de C.V. (each representing 10 Series B shares)

Hims & Hers Health Inc. Class A Common Stock

Coeur Mining Inc. Common Stock

Alamos Gold Inc. Class A Common Shares

Vista Energy S.A.B. de C.V. American Depositary Shares each representing one series A share with no par value

Click here to get full coverage on Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results  PR Newswire

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Click here to get full coverage on Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts - Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts  Yahoo Finance

Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts - Yahoo Finance

Click here to get full coverage on BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More  Nasdaq

BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Click here to get full coverage on (BHVN) Long Term Investment Analysis - news.stocktradersdaily.com

(BHVN) Long Term Investment Analysis  news.stocktradersdaily.com

(BHVN) Long Term Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine  Stock Titan

Biohaven's Next-Gen Neuroscience Pipeline: 13 Groundbreaking Studies Target Parkinson's and Migraine - Stock Titan

Click here to get full coverage on Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha

Biohaven stock slides as FDA delays drug review (BHVN:NYSE)  Seeking Alpha

Biohaven stock slides as FDA delays drug review (BHVN:NYSE) - Seeking Alpha

Click here to get full coverage on Biohaven Pharma (BHVN) Misses Q1 EPS by 47c - StreetInsider

Biohaven Pharma (BHVN) Misses Q1 EPS by 47c  StreetInsider

Biohaven Pharma (BHVN) Misses Q1 EPS by 47c - StreetInsider

Click here to get full coverage on INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN  PR Newswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - BHVN - PR Newswire

Click here to get full coverage on Noteworthy Friday Option Activity: BHVN, TDUP, PAYX - Nasdaq

Noteworthy Friday Option Activity: BHVN, TDUP, PAYX  Nasdaq

Noteworthy Friday Option Activity: BHVN, TDUP, PAYX - Nasdaq

Click here to get full coverage on Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting  PR Newswire

Biohaven Presents Data Across Innovative Neuroscience Portfolio at the 2025 American Academy of Neurology (AAN) Annual Meeting - PR Newswire

Click here to get full coverage on Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports Third Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300  PR Newswire

Biohaven Reports Positive Degrader Data Achieving > 80% Sustained Reductions in Total IgG with Potential First-in-Class BHV-1300 - PR Newswire

Click here to get full coverage on Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity  PR Newswire

Biohaven Provides Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity - PR Newswire

Click here to get full coverage on Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia  PR Newswire

Biohaven Announces FDA Acceptance and Priority Review of Troriluzole New Drug Application for the Treatment of Spinocerebellar Ataxia - PR Newswire

Click here to get full coverage on Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares  PR Newswire

Biohaven Announces Pricing of $250 Million Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates  PR Newswire

Biohaven Reports Positive Phase 1 Degrader Data, Achieving Deep Targeted IgG Reductions in the Lowest Subcutaneous Dose Tested; Announces NDA Submission for Troriluzole in SCA and Provides Other Key Program Updates - PR Newswire

Click here to get full coverage on Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares  PR Newswire

Biohaven Announces Proposed Public Offering of Common Shares - PR Newswire

Click here to get full coverage on Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio  PR Newswire

Biohaven Highlights Portfolio Progress, Innovation, and Anticipated Milestones at the 43rd Annual J.P. Morgan Healthcare Conference; Reports Positive Degrader Data with Rapid, Deep, and Selective Lowering of Galactose-Deficient IgA1 with Next Generatio - PR Newswire

Click here to get full coverage on Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN  Nasdaq

Notable Thursday Option Activity: CELH, AMD, BHVN - Nasdaq

Click here to get full coverage on Biohaven (BHVN) Shares Dip Following FDA Decision | BHVN Stock N - GuruFocus

Biohaven (BHVN) Shares Dip Following FDA Decision | BHVN Stock N  GuruFocus

Biohaven (BHVN) Shares Dip Following FDA Decision | BHVN Stock N - GuruFocus

Click here to get full coverage on Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital - StreetInsider

Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital  StreetInsider

Biohaven Pharma (BHVN) Announces Investment up to $600 Million by Oberland Capital - StreetInsider

Click here to get full coverage on First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven - Stock Titan

First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven  Stock Titan

First-Ever Treatment for Fatal Ataxia Disease Faces Critical FDA Decision: What's Next for Biohaven - Stock Titan

Click here to get full coverage on Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Yahoo Finance

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21  Yahoo Finance

Jim Cramer Says Biohaven (BHVN) Is “Too Cheap” and He’s a Buyer at $21 - Yahoo Finance

Click here to get full coverage on Biohaven (BHVN) Downgraded by RBC Capital with Price Target Cut - GuruFocus

Biohaven (BHVN) Downgraded by RBC Capital with Price Target Cut  GuruFocus

Biohaven (BHVN) Downgraded by RBC Capital with Price Target Cut - GuruFocus

Click here to get full coverage on Why Biohaven (BHVN) Stock Is Rallying Today - Yahoo Finance

Why Biohaven (BHVN) Stock Is Rallying Today  Yahoo Finance

Why Biohaven (BHVN) Stock Is Rallying Today - Yahoo Finance

Click here to get full coverage on Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments  PR Newswire

Biohaven Reports Second Quarter 2024 Financial Results and Recent Business Developments - PR Newswire

Click here to get full coverage on Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease - Stock Titan

Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease  Stock Titan

Biohaven Lands Massive $600M Backing to Advance First-Ever Treatment for Rare Genetic Disease - Stock Titan

Click here to get full coverage on Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Independent Director of Biohaven John Childs Buys More Stock  simplywall.st

Independent Director of Biohaven John Childs Buys More Stock - simplywall.st

Click here to get full coverage on Biohaven (BHVN) Shares Drop Over 17% Amid Market Activity | BHVN Stock News - GuruFocus

Biohaven (BHVN) Shares Drop Over 17% Amid Market Activity | BHVN Stock News  GuruFocus

Biohaven (BHVN) Shares Drop Over 17% Amid Market Activity | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target - GuruFocus

Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target  GuruFocus

Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Stock Dips Significantly | BHVN Stock News - GuruFocus

Biohaven (BHVN) Stock Dips Significantly | BHVN Stock News  GuruFocus

Biohaven (BHVN) Stock Dips Significantly | BHVN Stock News - GuruFocus

Click here to get full coverage on BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Business Wire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm  Business Wire

BHVN Investors Have Opportunity to Join Biohaven Ltd. Fraud Investigation with the Schall Law Firm - Business Wire

Click here to get full coverage on Biohaven (BHVN) Receives Downgrade Amid Regulatory Concerns | BH - GuruFocus

Biohaven (BHVN) Receives Downgrade Amid Regulatory Concerns | BH  GuruFocus

Biohaven (BHVN) Receives Downgrade Amid Regulatory Concerns | BH - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Shares Drop Significantly Amid Market Fluctuatio - GuruFocus

Biohaven (BHVN) Shares Drop Significantly Amid Market Fluctuatio  GuruFocus

Biohaven (BHVN) Shares Drop Significantly Amid Market Fluctuatio - GuruFocus

Click here to get full coverage on Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN)  Seeking Alpha

Biohaven's Exciting Year Of Catalysts (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on How the (BHVN) price action is used to our Advantage - news.stocktradersdaily.com

How the (BHVN) price action is used to our Advantage  news.stocktradersdaily.com

How the (BHVN) price action is used to our Advantage - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus

Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline  GuruFocus

Biohaven (BHVN) Shares Dip as FDA Extends Drug Review Timeline - GuruFocus

Click here to get full coverage on BHVN Strengthens Financial Position and Advances Strategic Initiatives | BHVN Stock News - GuruFocus

BHVN Strengthens Financial Position and Advances Strategic Initiatives | BHVN Stock News  GuruFocus

BHVN Strengthens Financial Position and Advances Strategic Initiatives | BHVN Stock News - GuruFocus

Click here to get full coverage on Biohaven (BHVN) Target Price Adjusted Amid Financing Concerns | - GuruFocus

Biohaven (BHVN) Target Price Adjusted Amid Financing Concerns |  GuruFocus

Biohaven (BHVN) Target Price Adjusted Amid Financing Concerns | - GuruFocus

Click here to get full coverage on Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts?  Insider Monkey

Is Biohaven Ltd. (BHVN) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Insider Monkey

Click here to get full coverage on Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (NYSE:BHVN) - Seeking Alpha

Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (NYSE:BHVN)  Seeking Alpha

Biohaven Is Now A Compelling Contrarian Play Before Troriluzole's FDA Verdict (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In?  Yahoo Finance

Do Analysts Think That Biohaven Pharmaceutical Holding Company Ltd. (BHVN) Is a Good GLP-1 and Weight Loss Stock to Invest In? - Yahoo Finance

Click here to get full coverage on (BHVN) Proactive Strategies - news.stocktradersdaily.com

(BHVN) Proactive Strategies  news.stocktradersdaily.com

(BHVN) Proactive Strategies - news.stocktradersdaily.com

Click here to get full coverage on Biohaven (BHVN) Awaits FDA Decision on Troriluzole for Spinocere - GuruFocus

Biohaven (BHVN) Awaits FDA Decision on Troriluzole for Spinocere  GuruFocus

Biohaven (BHVN) Awaits FDA Decision on Troriluzole for Spinocere - GuruFocus

Click here to get full coverage on Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha

Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN)  Seeking Alpha

Biohaven's Revenue Path: SCA And Obesity Therapies (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Amid firestorm over covering ‘Manipur’ on bus, Governor airlifted to Raj Bhavan - The Indian Express

Amid firestorm over covering ‘Manipur’ on bus, Governor airlifted to Raj Bhavan  The Indian Express

Amid firestorm over covering ‘Manipur’ on bus, Governor airlifted to Raj Bhavan - The Indian Express

Click here to get full coverage on Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha

Biohaven: A Complicated Tale (NYSE:BHVN)  Seeking Alpha

Biohaven: A Complicated Tale (NYSE:BHVN) - Seeking Alpha

Click here to get full coverage on Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - The Motley Fool

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March  The Motley Fool

Why Biotech Stocks Such as Biohaven, Recursion Pharmaceuticals, and CRISPR Therapeutics Plunged in March - The Motley Fool

Click here to get full coverage on Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo - GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo  GuruFocus

Biohaven (BHVN) Price Target Cut by Baird Amid Regulatory Develo - GuruFocus

Click here to get full coverage on Earnings Flash (BHVN) BIOHAVEN LTD. Reports Q1 Loss $-1.64 Per Share, vs. FactSet Est of $-1.70 - marketscreener.com

Earnings Flash (BHVN) BIOHAVEN LTD. Reports Q1 Loss $-1.64 Per Share, vs. FactSet Est of $-1.70  marketscreener.com

Earnings Flash (BHVN) BIOHAVEN LTD. Reports Q1 Loss $-1.64 Per Share, vs. FactSet Est of $-1.70 - marketscreener.com

Click here to get full coverage on Manipur stir forces governor to fly from airport to Raj Bhavan - Times of India

Manipur stir forces governor to fly from airport to Raj Bhavan  Times of India

Manipur stir forces governor to fly from airport to Raj Bhavan - Times of India

Click here to get full coverage on Biohaven price target lowered to $63 from $69 at Morgan Stanley - Yahoo Finance

Biohaven price target lowered to $63 from $69 at Morgan Stanley  Yahoo Finance

Biohaven price target lowered to $63 from $69 at Morgan Stanley - Yahoo Finance

Click here to get full coverage on (BHVN) Investment Analysis and Advice - news.stocktradersdaily.com

(BHVN) Investment Analysis and Advice  news.stocktradersdaily.com

Biohaven Pharmaceutical Holding Co Ltd (BHVN)

Price Chart

Key Statistics

Technicals

About BHVN

Latest News

Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results - PR Newswire

Biohaven Ltd. (BHVN): Among Stocks That Will Bounce Back According To Analysts - Yahoo Finance

BIOHAVEN Earnings Preview: Recent $BHVN Insider Trading, Hedge Fund Activity, and More - Nasdaq

Advanced Charts

Top Gainers

Top Losers